Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a note issued to investors on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX opened at $0.65 on Thursday. Eagle Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $9.10. The firm has a 50 day moving average of $1.74 and a two-hundred day moving average of $3.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EGRX. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals during the 3rd quarter valued at about $59,000. Mackenzie Financial Corp acquired a new stake in Eagle Pharmaceuticals during the second quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $65,000. Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $76,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.